Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

No-Needle chemo patch takes aim at skin cancer

NCT ID NCT06608238

Disease control Sponsor: SkinJect, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a microneedle patch that delivers the chemotherapy drug doxorubicin directly into nodular basal cell carcinoma, a common skin cancer. 90 adults with small, untreated tumors received either a low-dose, high-dose, or no-drug patch. The goal was to see if the patch could clear the cancer both visually and under a microscope, with the tumor removed at the end for confirmation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
doxorubicin delivered via microneedle patch
What this could lead to
If successful, this could offer a needle-free, targeted treatment for common skin cancers, potentially reducing the need for surgery.
What could go wrong
This is a small, early-phase study (90 people) and results may not apply to larger or more aggressive tumors. The treatment is not a cure and requires follow-up excision.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

90 people

The number who actually took part.

Started

Sep 2024

Finished

Mar 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: 1. Male or non-pregnant female ≥ 18 years of age at time of consent. 2. Clinical diagnosis of a primary, previously untreated, histologically confirmed nodular Basal Cell Carcinoma (nBCC) lesion suitable for excision (at end of the study) with a minimum diameter of 0.5 cm and with a maximum longest diameter of 1.3 cm at the time of biopsy and Visit 2/Baseline. Key Exclusion Criteria: 1. Pregnant, lactating, or planning to become pregnant. 2. nBCC is located on the face, scalp, digits, mucosa, or skin that is scarred or previously treated with radiation. 3. History of treated nBCC lesion recurrence or basal cell nevus syndrome. 4. Active malignancy, excluding non-metastatic prostate cancer, other cutaneous basal or squamous cell carcinomas, and carcinoma of the cervix. 5. Used topical immunomodulators within 2 cm of the Target Lesion within the 4 weeks prior to Visit 2/Baseline or after the confirmatory biopsy. 6. Used the following topical agents within 2 cm of the Target Lesion within the 4 weeks prior to Visit 2/Baseline or after the confirmatory biopsy: aminolevulinic acid, 5-fluorouracil, diclofenac, ingenol mebutate, tirbanibulin, or imiquimod. 7. Has been treated with liquid nitrogen, surgical excision or curettage within 2 cm of the Target Lesion within 4 weeks prior to Visit 2/Baseline or after the confirmatory biopsy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Nodular basal cell carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

basal cell carcinoma nodular basal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Nodular basal cell carcinoma

Contacts and locations

Locations

  • American Skin and Cancer Center - Site#2

    Knoxville, Tennessee, 37909, United States

  • Arlington Dermatology - Site #1

    Rolling Meadows, Illinois, 60008, United States

  • Clinical Trials Management, LLC- Site #5

    Mandeville, Louisiana, 70448, United States

  • HIckory Dermatology Research Center

    Hickory, North Carolina, 28602, United States

  • Nottingham University Hospitals NHS Trust

    Nottingham, East Midlands, NG5 1PB, United Kingdom

  • Oak Dermotology - site 07

    Naperville, Illinois, 60563, United States

  • Paradigm Research -Site #6

    San Diego, California, 92108, United States

  • Rao Dermatology - Site #3

    Highlands, New Jersey, 07716, United States

  • Rao Dermotology West Coast -Site #4

    Fresno, California, 93720, United States

  • Therapeutics Clinical Research -site 08

    San Diego, California, 92123, United States

  • Virginia Clinical Research Inc - site 11

    Norfolk, Virginia, 23502, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.